|
Synonyms: GAP-134 | ZP-1609 | ZP1609
Compound class:
Synthetic organic
Comment: Danegaptide (GAP-134, and formerly ZP 1609) is an orally bioavailable gap-junction modifier that targets connexin-43. It is the successor molecule to rotigaptide which was intravenously administered. Like rotigaptide, danegaptide was initially intended for the treatment of chronic heart conditions such as ventricular arrhythmias and atrial fibrillation, but focus was diverted to the role of connexin-43 modulation in diabetic retinopathy.
|
|
|||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| (2S,4R)-1-(2-aminoacetyl)-4-benzamidopyrrolidine-2-carboxylic acid |
Synonyms ![]() |
| GAP-134 | ZP-1609 | ZP1609 |
Database Links ![]() |
|
| CAS Registry No. | 943134-39-2 (source: PubChem) |
| ChEBI | CHEBI:177853 |
| ChEMBL Ligand | CHEMBL560592 |
| DrugBank Ligand | DB11821 |
| PubChem CID | 16656685 |
| Search Google for chemical match using the InChIKey | BIZKIHUJGMSVFD-MNOVXSKESA-N |
| Search Google for chemicals with the same backbone | BIZKIHUJGMSVFD |
| UniChem Compound Search for chemical match using the InChIKey | BIZKIHUJGMSVFD-MNOVXSKESA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | BIZKIHUJGMSVFD-MNOVXSKESA-N |